<DOC>
	<DOCNO>NCT00716742</DOCNO>
	<brief_summary>To investigate effectiveness new IOP-lowering therapy , prescribe normal clinical practice , large patient number . Patients assessed baseline , follow-up visit ( follow-up visit variable per physician discretion ) final follow-up visit .</brief_summary>
	<brief_title>Safety Efficacy Study Bimatoprost , Latanoprost , Travoprost Patients With Elevated Intraocular Pressure ( IOP ) Open-angle Glaucoma ( OAG )</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>A diagnosis Primary OpenAngle Glaucoma Ocular Hypertension newly diagnose OR present insufficiently control IOP current medication ( opinion treat physician ) Patient eye treat Contraindications per product labelling apply . Patients ophthalmic comorbidity influence visual field deterioration optic nerve head damage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>